Topical finasteride: the same drug, a different legal object

The pitch for topical finasteride is intuitive: put the drug where the follicles are and less of it reaches everywhere else. The intuition is not unreasonable. What matters is that it has not been established, and that in the United States the products being sold on the strength of it have never been assessed by a regulator at all.

It helps to hold the three forms of this drug apart before going further. The tablet has held a US hair-loss licence since 1997 and is licensed across the UK and EU. Dutasteride has no hair-loss licence in any of those places, so using it for hair is off-label — although Japan approved it for exactly that in 2015. Topical finasteride sits in a third category, and which category depends entirely on where you are standing.

Why the American and European answers differ

In the US, the FDA stated in its compounding alert of 22 April 2025 that there is currently no FDA-approved topical formulation of finasteride, alone or combined with anything else, and that compounded topical products therefore have no FDA-approved labelling. Compounded drugs are not FDA-approved, which means the agency has not evaluated their safety, effectiveness or quality before marketing.

In Europe the picture is different. The EMA's 2025 referral describes medicines containing finasteride as cutaneous spray solutions, authorised in various member states to treat early male pattern hair loss — a licensed product, assessed, with approved product information. So "is topical finasteride approved?" has no single answer; it depends which country's regulator you are asking, and a US telehealth product is not the European spray.

What compounding is, and what it is not

Compounding is the preparation of a medicine to order — combining, mixing or altering ingredients for a particular patient or, in the case of an outsourcing facility, in batches. It is a real and useful practice: a child who cannot swallow tablets, an allergy to a dye, a strength that no manufacturer makes.

What it is not is an approval. The FDA's own framing is the clearest available: compounded drugs are not FDA-approved, which means the agency has not evaluated their safety, effectiveness or quality prior to marketing. So the ordinary chain of assurance you get from a licensed medicine — a dossier assessed, a label written and policed, batch consistency demonstrated — is absent, and what replaces it is the reputation of the pharmacy.

That is a very different proposition from a product sold to thousands of people by a marketing platform. A one-off preparation for a named patient is the case compounding law is built around; a nationally advertised hair-loss product is something else wearing the same coat.

What the FDA actually reported

The alert is short and specific. Between 2019 and 2024 the FDA's adverse event reporting system received 32 cases involving compounded topical finasteride. Absorption of finasteride through the skin into the bloodstream, it says, is expected. The reported events were consistent with those associated with the approved oral products: erectile dysfunction, anxiety, suicidal ideation, brain fog, depression, fatigue, insomnia, decreased libido and testicular pain.

Then the sentence that undoes the entire marketing premise: most of the reports the FDA received stated that the adverse events continued to persist after the product was discontinued.

The agency also recorded something about how these products were being sold. Some people said they had not been made aware of the potential adverse events; others reported being told by prescribers that there was no risk of any adverse event because the product was topical. Several said their lives had been ruined by the symptoms. Thirty-two reports is a small number and the FDA does not present it as an incidence — but the pattern inside them is about what patients were told, and that part is not a statistical question.

The risk a tablet does not have

One hazard belongs to topicals alone. Approved finasteride tablets are coated, and the coating is why the label says normal handling is safe provided the tablet is not crushed or broken — the concern being exposure of a pregnant woman and, through her, a male fetus. A cream, gel or spray has no coating. The FDA names a greater potential risk of inadvertent exposure to others, specifically women, through transfer of the applied product.

That is not a hypothetical to be managed by being careful. It is the reason pregnancy and fertility have their own page here, and it is a question to put to a prescriber before anything is applied in a shared bathroom.

Local effects, which are real and mostly dull

Alongside the systemic concerns the FDA lists local reactions: irritation, redness, dryness and scaling, stinging and burning. These are the ordinary complaints of anything applied to a scalp daily, and they are also the commonest reason people stop using topicals of any kind.

What about the European spray's safety record?

This is where the EU review is genuinely informative. Having confirmed suicidal ideation as a side effect of the finasteride tablets, the same review found no evidence linking suicidal ideation to the finasteride skin sprays, and made no change to their product information.

Read that carefully before it gets over-read. A licensed spray with far smaller exposure and fewer users generating fewer reports is a different evidence base, not a demonstration of safety. The EMA did not say the spray is safe where the tablet is not; it said the data it reviewed did not link the spray to that specific risk.

"No approved product" is not "no evidence"

It is worth being precise about what the American situation does and does not imply. Trials of topical finasteride exist in the published literature, and a European regulator assessed a spray and licensed it, which means a dossier satisfied somebody whose job is to be unsatisfied. The absence of a US approval is a fact about a filing and a market, not proof that the idea does not work.

But the reverse inference is the one being sold, and it does not hold either. A licensed European spray tells you nothing about the concentration, the vehicle, the batch consistency or the absorption of an unrelated compounded product made to a different recipe on another continent. Those are different medicines that share an active ingredient, which is exactly the distinction the FDA's alert is drawing.

How to think about it

If a service offers you a compounded topical, three questions are fair and answerable. Which regulator has assessed this exact formulation, and if none has, what does that mean for what is known about it? What is the evidence that it produces less systemic exposure than the tablet, and who published it? And what is the plan for people sharing your home, given the transfer warning?

If the answer to the first is a version of "it is topical, so it is safer", that is the exact claim the FDA recorded patients being given. The underlying medicine, with its licensed uses and trial figures, is set out on the finasteride page; the argument about lasting effects is on the post-finasteride syndrome page.